Patents by Inventor Kwan Hyung Cho

Kwan Hyung Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210139424
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 13, 2021
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Publication number: 20210141882
    Abstract: Disclosed herein are an apparatus and method for user authentication based on multiple pieces of biometric information. The apparatus may include one or more processors and executable memory for storing at least one program executed by the one or more processors. The at least one program receives multiple pieces of biometric information from the client device of a user, generates the personal identifier of the user using a neural network and a Bloom filter algorithm, and checks the similarity between the personal identifier of the user and each of personal identifiers previously registered in a database, thereby authenticating the user.
    Type: Application
    Filed: October 8, 2020
    Publication date: May 13, 2021
    Inventors: Kwan-Tae CHO, Seok-Hyun KIM, Soo-Hyung KIM, Seung-Hyun KIM, Young-Sam KIM, Jong-Hyouk NOH, Sang-Rae CHO, Young-Seob CHO, Jin-Man CHO, Jung-Yeon HWANG
  • Patent number: 10913715
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 9, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10889545
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 12, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10683268
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: June 16, 2020
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Publication number: 20200181082
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Application
    Filed: December 18, 2019
    Publication date: June 11, 2020
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Publication number: 20200123106
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 23, 2020
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10487053
    Abstract: The present invention provides a novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described acid addition salt can have not only excellent proton pump inhibitory activity, gastric damage inhibitory activity and defensive factor-enhancing effect, but also excellent eradication activity against H. pylori and thus can be effectively used for the prevention and treatment of gastrointestinal injury due to gastrointestinal track ulcer, gastritis, reflux esophagitis, or H. pylori.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 26, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Publication number: 20190322622
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Application
    Filed: May 14, 2019
    Publication date: October 24, 2019
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10336695
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 2, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Publication number: 20190047953
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Application
    Filed: March 17, 2017
    Publication date: February 14, 2019
    Applicant: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri KIM, Kwan Hyung CHO
  • Publication number: 20190031609
    Abstract: The present invention provides a novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described acid addition salt can have not only excellent proton pump inhibitory activity, gastric damage inhibitory activity and defensive factor-enhancing effect, but also excellent eradication activity against H. pylori and thus can be effectively used for the prevention and treatment of gastrointestinal injury due to gastrointestinal track ulcer, gastritis, reflux esophagitis, or H. pylori.
    Type: Application
    Filed: March 17, 2017
    Publication date: January 31, 2019
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 7097967
    Abstract: The present invention provides a method of predicting a food-drug interaction in vivo, in the case of an orally administered drug interactive with digestive enzymes in the gastrointestinal tract, by measuring the activity of the drug to the digestive enzymes in vitro, which is based on the fact that the ingestion of foods causes the absorption of drug in vivo to decrease due to the above interaction between a drug and digestive enzymes. The present invention further provides methods of minimizing the change of absorption in vivo caused by the ingestion of foods by reducing the action of digestive enzymes, for example, introduction of prodrugs, modification of the chemical structure of drug, design of drug formulation, etc.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: August 29, 2006
    Assignee: LG Life Sciences Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho, Sun Hwa Lee, Suk Kyoon Yoon, Hee Dong Park, Kyung Ha Chung, Ho Jun Kim, Han Joo Maeng, Tae Hun Kim, Bong Chan Kim, Sung Ji Kim
  • Publication number: 20050154229
    Abstract: The present invention relates to a maleic acid salt of (2S)-N-{5-[amino(imino)methyl]-2-thienyl}methyl-1-{(2R)-2-[(carboxymethyl)amino]-3,3-diphenylpropanoyl}-2-pyrrolidinecarboxamide.
    Type: Application
    Filed: March 21, 2003
    Publication date: July 14, 2005
    Inventors: Aeri Kim, Jae-Hyeon Park, Suk-Kyoon Yoon, Cheol-Won Park, Kwan-Hyung Cho
  • Publication number: 20050113309
    Abstract: The present invention relates to crystalline forms of (2S)-N-5-[amino(imino)methyl]-2-thienyl-methyl-1-(2R)-2-[(carboxymethyl)amino]-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide nH2O.
    Type: Application
    Filed: March 21, 2003
    Publication date: May 26, 2005
    Inventors: Aeri Kim, Jae-Hyeon Park, Suk-Kyoon Yoon, Bong-Chan Kim, Sung-Ji Kim, Kwan-Hyung Cho
  • Publication number: 20040229821
    Abstract: The present invention provides an orally administrable pharmaceutical composition for preventing the decrease in the bioavailability of a drug after food intake, comprising, i) said drug; and ii) a pharmaceutically acceptable bioadhesive polymer, particularly for effectively preventing the decrease in the drug absorption rate due to interaction with digestive enzymes or food ingredients after food intake.
    Type: Application
    Filed: February 23, 2004
    Publication date: November 18, 2004
    Inventors: Ae-Ri Kim, Kwan-Hyung Cho, Ji-Hye Lee, Sun-Hwa Lee, Ho-Jun Kim, Han-Joo Maeng, Hee-Dong Park, Tae-Hun Kim, Bong-Chan Kim, Sung-Ji Kim, Kyo-Seok Choo
  • Publication number: 20040081641
    Abstract: The present invention provides a method of predicting a food-drug interaction in vivo, in the case of an orally administered drug interactive with digestive enzymes in the gastrointestinal tract, by measuring the activity of the drug to the digestive enzymes in vitro, which is based on the fact that the ingestion of foods causes the absorption of drug in vivo to decrease due to the above interaction between a drug and digestive enzymes. The present invention further provides methods of minimizing the change of absorption in vivo caused by the ingestion of foods by reducing the action of digestive enzymes, for example, introduction of prodrugs, modification of the chemical structure of drug, design of drug formulation, etc.
    Type: Application
    Filed: October 24, 2002
    Publication date: April 29, 2004
    Applicant: LG LIFE SCIENCES LTD.
    Inventors: Aeri Kim, Kwan Hyung Cho, Sun Hwa Lee, Suk Kyoon Yoon, Hee Dong Park, Kyung Ha Chung, Ho Jun Kim, Han Joo Maeng, Tae Hun Kim, Bong Chan Kim, Sung Ji Kim